🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to scientists.

A Worldwide Public Health Issue

Cases of gonorrhoea are on the rise globally, with data suggesting in excess of 82 million new cases each year. Especially elevated rates are observed in the African continent and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the context of growing infection rates, escalating drug resistance and the extremely scarce treatment choices at this time.”

Medical experts are deeply concerned about the rise in treatment-resistant strains. The global health body has classified it as a "high-priority threat". A tracking program found that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Secure Approval

Zoliflodacin, alternatively called a brand name, was cleared by the US FDA in December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Scientists believe that specific application of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GSK, gained clearance in concurrent days. This treatment, which is also used to treat UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to bring it to fruition.

“This approval marks a significant shift in the treatment of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Results and Worldwide Availability

According to findings published in a major medical journal, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This places it at an similar efficacy with the current standard treatment, which uses two antibiotics. The study involved over 900 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the authority to register and commercialise the drug in many developing nations.

Medical professionals on the front lines have expressed optimism. Access to a one-pill regimen of this kind is hailed as a "critical tool" for gonorrhoea control. This is deemed vital to lessen the impact of the disease for people and to stop the proliferation of extremely resistant gonorrhoea worldwide.